Influence of Cardiopulmonary Rehabilitation on Cardiorespiratory Adaptation in Patients With Pulmonary Hypertension

Influence of Cardiopulmonary Rehabilitation on Cardiorespiratory Adaptation in Patients With Pulmonary Hypertension: A Comparative Experimental Study

This study aims to investigate the effect of cardiopulmonary rehabilitation on cardiorespiratory parameters and functional capacity in patients with pulmonary hypertension.

Study Overview

• Status: Not yet recruiting
• Conditions: Pulmonary Hypertension Due to Lung Disease (Disorder)
• Intervention / Treatment: Behavioral: cardiopulmonary rehabilitation in the form of moderate-intensity interval aerobic training; Device: Inspiratory Muscle Training; Other: Medical treatment

Detailed Description

Pulmonary hypertension is a progressive disease associated with reduced exercise capacity, respiratory muscle weakness, and impaired quality of life. Exercise training and respiratory muscle training have been shown to improve physical performance and quality of life in patients with pulmonary hypertension.

forty-two medically stable patients with Group III pulmonary hypertension due to lung diseases (obstructive and restrictive) will participate in this comparative experimental study. Participants will receive cardiopulmonary rehabilitation consisting of moderate-intensity interval aerobic training and inspiratory muscle training in addition to routine medical treatment. Outcome measures will include echocardiographic parameters, pulmonary function, six-minute walk distance, estimated VO2max, dyspnea severity, and quality of life. The study aims to evaluate the influence of cardiopulmonary rehabilitation on cardiorespiratory adaptation in patients with pulmonary hypertension.

• Study Type: Interventional
• Enrollment (Estimated): 42
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Rana Essam El Din Abd Elbar, Assistant lecturer; Phone Number: 01013981766; Email: rana.essam@acu.edu.eg

Study Locations

• Egypt
  • Giza, Egypt
    • Faculty of Physical Therapy ,Cairo University
    • Contact: Rana Essam El Din Abd Elbar, Assistant lecturer; Phone Number: 01013981766; Email: rana.essam@acu.edu.eg
    • Contact: Rana Essam El Din Abd Elbar, assistant lect P.T; Email: rana.essam@acu.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

- a)Medically stable pulmonary hypertension patients who were under optimized medical therapy. b)Pulmonary artery pressure ≥ 25 mmHg confirmed by RT side heart catheterization.

c)Forty two male patients with group 3 pulmonary hypertension (Chest cause) include Obstructive lung disease ( COPD and sleep apnea ) and restrictive lung disease (ILD). d)The patients' ages will range from 45 to 65 years old. e)BMI (25 - 34.9) kg/m2. f)World Health Organization (WHO) classification of functional classes II to III ( class II are patients with pulmonary hypertension who have a mild limitation of physical activity )(class III are patients with pulmonary hypertension who have a marked limitation of physical activity

Exclusion Criteria:

• g)Uncontrolled systemic HTN. h)Other types of pulmonary hypertension.. i)Smoker j)Any condition of kidney failure. k)Neurological or musculoskeletal conditions that interfere with gait

  l)Impaired vision and/or hearing.

  m)Patients who are unable to follow verbal instructions. n)acute exacerbation condition. o)unstable angina, serious cardiac dysrhythmias on resting ECG.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: group III PH with obstructive lung disease; Group (A), (n =16) patients with group III PH with obstructive lung disease will receive cardiopulmonary Rehabilitation in the form of moderate-intensity interval aerobic training and inspiratory muscle training in addition to the routine medical treatment.	Behavioral: cardiopulmonary rehabilitation in the form of moderate-intensity interval aerobic training; Training will be conducted on a treadmill three times weekly for 12 weeks. Exercise intensity will progress from 30-40% to 60-70% of target heart rate. Each session will last 30 minutes and include warm-up and cool-down periods.; Device: Inspiratory Muscle Training; inspiratory muscle training will be performed using a Threshold Inspiratory Muscle Trainer (Philips Respironics). Training intensity will correspond to moderate-to-severe effort (3-5 on the Modified Borg Scale).
Experimental: group III PHT with restrictive lung disease; group (B), (n =16) patients with group III PHT with restrictive lung disease will receive cardiopulmonary rehabilitation in the form of moderate-intensity interval aerobic training and inspiratory muscle training in addition to the routine medical treatment.	Behavioral: cardiopulmonary rehabilitation in the form of moderate-intensity interval aerobic training; Training will be conducted on a treadmill three times weekly for 12 weeks. Exercise intensity will progress from 30-40% to 60-70% of target heart rate. Each session will last 30 minutes and include warm-up and cool-down periods.; Device: Inspiratory Muscle Training; inspiratory muscle training will be performed using a Threshold Inspiratory Muscle Trainer (Philips Respironics). Training intensity will correspond to moderate-to-severe effort (3-5 on the Modified Borg Scale).
Experimental: control group III PH with obstructive lung disease; Group (c), (n =5) patients with group III PH with obstructive lung disease will receive medical treatment only	Other: Medical treatment; medication
Experimental: control group III PHT with restrictive lung disease; Group (D), (n =5) patients with group III PH with restrictive lung disease will receive medical treatment only	Other: Medical treatment; medication

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
6-minute walk distance	total distance walked in 6 minutes	12 weeks
Maximal Oxygen Consumption	Estimated VO2max	12weeks
spirometry	FEV1, FVC, FEV1/FVC, MVV	12weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dyspnea Severity	Modified Borg Scale	12weeks
change Pulmonary Artery Pressure	pulmonary artery pressure estimated by ECHO	12weeks
change of total score of SF-12 Questionnaire) Quality of Life	more increase scores more increase quality of life	12weeks

Collaborators and Investigators

• Sponsor: Cairo University
• Investigators: Study Chair: NESREEN GHAREEB MOHAMED EL-NAHAS, Prof PT, faculty of P.T. Cairo University; Study Chair: HEBA AHMED ALI ABDEEN, Prof, faculty of P.T. Cairo University; Study Chair: HEND ABD EL-MONAEM ABD EL-MONAEM, Lecturer of physical therapy, faculty of P.T. Cairo University; Study Chair: REEM IBRAHIM EL KORASHY, prof of pulmonology, Cairo University

Study record dates

Study Major Dates

• Study Start (Estimated): June 13, 2026
• Primary Completion (Estimated): September 13, 2026
• Study Completion (Estimated): September 13, 2026

Study Registration Dates

• First Submitted: June 10, 2026
• First Submitted That Met QC Criteria: June 10, 2026
• First Posted (Actual): June 15, 2026

Study Record Updates

• Last Update Posted (Actual): June 15, 2026
• Last Update Submitted That Met QC Criteria: June 10, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Pulmonary Hypertension Cardiopulmonary Rehabilitation Inspiratory Muscle Training Exercise Training Functional Capacity Pulmonary Function
• Other Study ID Numbers: P.T.REC/012/005518

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: to protect participant confidentiality

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No